medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2009, Number 1

<< Back Next >>

Rev Biomed 2009; 20 (1)

Pentoxifylline in the fulminant hepatitis: Report of two cases

Jiménez-Luévano MA, Cortés-Nuño S, Rocha-López AN, Cervantes-Rodríguez MTG, Bravo-Cuéllar A, Franco-Topete R, Abascal-Medina CG

Language: Spanish
References: 29
Page: 33-39
PDF size: 0. Kb.


ABSTRACT

Introduction. Acute Hepatitis as a clinical entity caused mainly by viruses or chemical agents. Its prognostic is generally fatal, reaching up to 70-90% mortality. It is well known that in this pathology, the oxidative stress and proinflamatory cytokines (TNF α, IL-1 and IL-6) are very important factors that contribute to the negative prognostic of the disease. On the other hand, besides the haemorrhogical effects of pentoxyphillin, it also shows anti-oxidant activity and is a strong inhibitor of the proinflamatory cytokines secretion. This paper reports two paediatric cases of subacute hepatitis, caused by the hepatitis virus type A. Clinic Cases. Hepatitis virus A, diagnosed according to the criteria of the British King’s College. Both cases were submitted for medical treatment with anti-ammonium measures with 1.5 gr of Ornitate-L-L-Aspartate by nasogastric tube, vitamin K 2 mg/12 h iv, mannitol 0.4 mg/kg/12 h iv sodium diphenylhydantoinate 3 mg/kg/8 h iv omeprazole 10 mg/12 h iv, metronidazol e 210 mg, fresh plasma, parenteral solutions with glucose at 10%, O2 3 litres/minute and hypercaloric diet based on vegetal fiber by nasogastric tube. Based on the foregoing, pentoxyphillin was added at of 70 mg iv/8 h. Both cases responded successfully to that and after 15 days of treatment, the patients were sent home safely. Commentaries: Although this report is not definitive, results show the potential of pentoxyphillin to encourage its use in a future study for the treatment of acute hepatitis.


REFERENCES

  2. Heo NY, Lim YS, Kang JM, Oh SI, Park CS, Jung SW, et al. Clinical features of fulminant hepatic failure in a tertiary hospital with a liver transplant center in Korea. Korean J Hepatol 2006; 12:82-92.

  3. Alegre F, Moreno D, Quiroga J. Infección Aguda por el VHB. An Sist Sanit Navar 2004; 27:17-25.

  4. Emmet BK. Insuficiencia hepática aguda. Rev Gastroenterol Mex 2005; 70:56-62.

  5. Infante-Velázquez M. Insuficiencia hepática aguda.Rev Cubana Med Milit Cuba 2001; 30:63-70.

  6. Hernández-Téllez IE, Ibarra-Hirales E; Villatoro-Cruz A; López-Morales OO; Frías-Salcedo JA. Hepatitis Fulminante. Evolución, tratamiento, pronóstico y mortalidad. Rev Sanid Milit Mex 1995; 49:63-66.

  7. Ruiz-Moreno M, Leal OA, Millán JA. Hepatitis Víricas; Apuntes del XXIX Congreso Nacional Ordinario de Pediatría de la A.E.P. Servicio de Pediatría, Fundación Jiménez Díaz 2000, Madrid, España.

  8. Vento S, Garofano T, Renzini C, Cainelli F, Casali F,Ghironzi G, et al. Fulminant Hepatitis associated with Hepatitis A Virus superinfection in patients with chronic Hepatitis C. New Engl J Med 1998; 338:286-90.

  9. Hernández-Estrada S, Aguilar DC, Lizardi CJ.Hepatitis por virus Epstein-Barr: Reporte de un caso. Med Sur 2005; 12:177-9.

  10. Halabe CJ, Angulo VF. Hepatitis viral. Rev Fac Med (Mex) 2000; 43:90-100.

  11. Jiménez-Escobar I, Flores-Nava G, Vázquez-Zavala G, Alba-Palacios RA, Lavalle-Villalobos A. Hepatopatía por ingestión de hongos silvestres. Presentación de dos casos. Rev Mex Pediatr 2005; 72:27-30.

  12. Garcia-Tsao G, Oude ER. Changing clinical patterns in acute liver failure. J Hepatol 2003; 39:660-61.

  13. Sotelo CN, López CG. Hepatitis Fulminante Relacionada a Virus. Experiencia en el Hospital Infantil del Estado de Sonora. 1977-1997. Bol Med Hosp Infant Mex 1997;14:40-47.

  14. Farci P, Alter HJ, Shimoda A, Govindarajan S,Cheung LC, Melpolder JC, et al. Hepatitis C virusassociated fulminant hepatic failure. N Engl J Med 1996; 335:631-34.

  15. Cabrera RA, Carrera SM, Juárez OR. Insuficiencia hepática fulminante. Medicina Interna de México 2001; 17:235-41.

  16. Giradles E, Lorraín F, Harás P. Hepatitis viral aguda,Manual de gastroenterología pediátrica: Oficina de Educación Médica (OEM) de la Pontificia Universidad Católica de Chile 2005:cap.6

  17. Vaquero J, Chung C, Blei AT. Brain Edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. J Hepatology 2003; 2:12-22.

  18. Lizardi CJ, Almeda VP. Insuficiencia hepática fulminante.Med Sur 2005; 12:149-53.

  19. Moreau R. Are nitric oxide synthases new players in the pathophysiology of fulminant hepatic failure? J Hepatol 2002; 37:678-80.

  20. Larsen FS, Häussinger D. Hepatic encephalopathy and nitric oxide. J Hepatol 2001; 34:610-12.

  21. Abdel-Salam OM, Baiuomy AR, El-Shehawy, Hassan NS. Effect of pentoxifylline on hepatic injury caused in the rat by the administration of carbon tetrachloride or acetaminophen. Pharmacol Rep 2005; 57:596-603.

  22. Sneed RA, Buchweitz JP, Jean PA, Ganey PE. Pentoxifylline attenuates bacterial lipopolysaccharideinduced enhancement of allyl alcohol hepatotoxicity. Toxicol Sci 2000; 56:203-10.

  23. Lerma-Díaz JM, Hernández-Flores G, Domínguez-Rodríguez JR, Ortíz-Lazareno PC, Gómez-Contreras P, Cervantes-Munguía R, et al. In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkBα phosphorilation. Immunology Letters 2006; 103:149-58.

  24. Gómez-Contreras PC, Hernández-Flores G, Ortiz-Lazareno PC, Del Toro-Arreola S, Delgado-Rizo V, Lerma-Díaz JM, et al. In Vitro induction of apoptosis in U937 cells by Perillyl alcohol with sensitization by pentoxifylline: Increased BCL-2 and Bax Protein Expression. Chemotherapy 2006; 52:308-15.

  25. Leifeld L, Fielenbach M, Dumoulin FL, Speidel N,Sauerbruch T, Spengler U. Inducible nitric oxide synthase (iNOS) expression in fulminant hepatic Failure. J Hepatol 2002; 37: 613-19.

  26. Castañón-González JA, Gallegos-Pérez H, Eid LGu,Pérez-Aispuro I, Vázquez-de Anda GF, Alvarado- Díez R, et al. Insuficiencia Hepática Fulminante. Re- porte de diez casos. Rev Asoc Mex Med Crit Ter Inten 1995; 9: 35-40.

  27. Gutierrez-Reyes G, Lopez-Ortal P, Sixtos S, Cruz S,Ramirez-Iglesias MT, Gutierrez-Ruiz, et al. Effect of Pentoxifylline on Levels of Pro-inflammatory Cytokines During Chronic Hepatitis C. Scand J Immunol 2006; 63:461-7.

  28. Voisin L, Breuille D, Ruot B, Ralliere C, Rambourdin F, Dalle M, et al. Cytokine modulation by PX dif- differently affected specific acute phase proteins during sepsis in rats. Am J Physiol 1998; 275:R1412-9.

  29. Kershenobich, D. Bases fisiopatológicas para la terapia de la esteatohepatitis alcohólica. Gastr Latinoam 2002; 13:64-66.




2020     |     www.medigraphic.com